The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: A matched cohort study

Critical Care

Volumn 18, Issue 1, 2014, Pages

  Shekar, Kiran ^a   Fraser, John F ^a   Taccone, Silvio ^b   Welch, Susan ^c   Wallis, Steven C ^a   Mullany, Daniel V ^a   Lipman, Jeffrey ^a   Roberts, Jason A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ERASME HOSPITAL   (Belgium)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; AGED; ARTICLE; CHROMATOGRAPHY; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DESCRIPTIVE RESEARCH; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG CLEARANCE; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; MIDDLE AGED; MONTE CARLO METHOD; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEPSIS; VOLUME OF DISTRIBUTION; ADOLESCENT; COMPARATIVE STUDY; CRITICAL ILLNESS; METABOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CRITICAL ILLNESS; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; RENAL REPLACEMENT THERAPY; SEPSIS; THIENAMYCINS; YOUNG ADULT;

EID: 84924237099     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0565-2     Document Type: Article

References (26)

1. Shekar K, Mullany DV, Thomson B, Ziegenfuss M, Platts DG, Fraser JF: Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients: a comprehensive review. Crit Care 2014, 18:219.
2. Brodie D, Bacchetta M: Extracorporeal membrane oxygenation for ARDS in adults. N Engl J Med 2011, 365:1905-1914.
3. Shekar K, Fraser JF, Smith MT, Roberts JA: Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012, 27:e749-718.
4. Jamal JA, Economou CJ, Lipman J, Roberts JA: Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012, 18:460-471.
5. Shekar K, Roberts JA, Smith MT, Fung YL, Fraser JF: The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol 2013, 13:7.
6. Shekar K, Fung YL, Diab S, Mullany DV, McDonald CI, Dunster KR, Fisquet S, Platts DG, Stewart D, Wallis SC, Smith MT, Roberts JA, Fraser JF: Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. Crit Care Resusc 2012, 14:105-111.
7. Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, Ghassabian S, Wallis SC, Levkovich B, Pellegrino V, McGuinness S, Parke R, Gilder E, Barnett AG, Walsham J, Mullany DV, Fung YL, Smith MT, Fraser JF: ASAP ECMO: antibiotic, sedative and analgesic pharmacokinetics during extracorporeal membrane oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol 2012, 12:29.
8. Shekar K, Roberts JA, McDonald CI, Fisquet S, Barnett AG, Mullany DV, Ghassabian S, Wallis SC, Fung YL, Smith MT, Fraser JF: Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care (London, England) 2012, 16:R194.
9. Shekar K, Roberts JA, Ghassabian S, Mullany DV, Wallis SC, Smith MT, Fraser JF: Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern? J Antimicrob Chemother 2013, 68:726-727.
10. Shekar K, Roberts JA, Ghassabian S, Mullany DV, Ziegenfuss M, Smith MT, Fung YL, Fraser JF: Sedation during extracorporeal membrane oxygenation-why more is less. Anaesth Intensive Care 2012, 40:1067-1069.
11. De Rosa FG, Corcione S, Pagani N, Stella ML, Urbino R, Di Perri G, Ranieri VM: High rate of respiratory MDR gram-negative bacteria in H1N1-ARDS treated with ECMO. Intensive Care Med 2013, 39:1880-1881.
12. Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P: Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med 2011, 12:277-281.
13. Aubron C, Cheng AC, Pilcher D, Leong T, Magrin G, Cooper DJ, Scheinkestel C, Pellegrino V: Infections acquired by adults who receive extracorporeal membrane oxygenation: risk factors and outcome. Infect Control Hosp Epidemiol 2013, 34:24-30.
14. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150.
15. Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, Goldrick PB, Lipman J: Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother 2010, 54:2974-2978.
16. Holford N: Wings for NONMEM. Available at: [ http://wfn.sourceforge.net ] (last accessed 03 October 2014).
17. Parke J, Holford NH, Charles BG: A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999, 59:19-29.
18. European Committee on Antimicrobial Susceptibility Testing: Fosfomycin: Rationale for the clinical breakpoints v 2013. [ http://www.eucast.org ]
19. McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351.
20. Roberts JA, Lipman J: Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851. quiz 859.
21. Roberts JA, Hope WW, Lipman J: Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents 2010, 35:419-420.
22. Askenazi DJ, Selewski DT, Paden ML, Cooper DS, Bridges BC, Zappitelli M, Fleming GM: Renal replacement therapy in critically ill patients receiving extracorporeal membrane oxygenation. Clin J Am Soc Nephrol 2012, 7:1328-1336.
23. Extracorporeal Life Support Organization. ECLS Registry Report, International Summary: Ann Arbor, MI; January 2014. 2013
24. Rohwedder RW, Bergan T, Thorsteinsson SB, Scholl H: Transintestinal elimination of ciprofloxacin. Diagn Microbiol Infect Dis 1990, 13:127-133.
25. Goncalves-Pereira J, Silva NE, Mateus A, Pinho C, Povoa P: Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients. BMC Pharmacol Toxicol 2014, 15:21.
26. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J: Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010, 49:1-16.